MedTrace Logo

Risk Stratification of COVID-19 Using Urine Biomarkers

NCT04681040 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 964

Last updated 2024-03-27

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in infected patients, it produces symptoms which range from completely asymptomatic to those expressing severe illness. Early recognition of those developing severe manifestations allows for rapid and appropriate intervention, including admission to intensive care unit and intensive care therapy, such as mechanical ventilation. A current problem is that only limited data exist predicting the clinical course of COVID-19. This study will determine whether non-invasive urinalysis is useful in assessing and predicting the severity or clinical course of patients with COVID-19.

Conditions

  • Covid19
  • Urine
  • Biomarker
  • Acute Respiratory Failure With Hypoxia

Sponsors & Collaborators

  • National Center for Global Health and Medicine, Japan

    lead OTHER_GOV

Principal Investigators

  • Eisei Noiri, M.D., Ph.D. · National Center for Global Health and Medicine

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2024-02-14
Completion
2024-03-25

Countries

  • United States
  • Brazil
  • Denmark
  • Japan
  • Philippines

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04681040 on ClinicalTrials.gov